Aligos Therapeutics (ALGS) Total Non-Current Liabilities (2019 - 2024)

Aligos Therapeutics (ALGS) has 6 years of Total Non-Current Liabilities data on file, last reported at $26.7 million in Q4 2024.

• Quarterly Total Non-Current Liabilities fell 16.17% year-over-year to $26.7 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $26.7 million (down 16.17% YoY) and the FY2024 annual result came in at $26.7 million, down 16.17% from the prior year.
• Total Non-Current Liabilities steadied at $26.7 million in Q4 2024, from $26.7 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $57.4 million in Q1 2022 to a low of $26.1 million in Q1 2024.
• A 5-year average of $39.7 million and a median of $42.3 million in 2021 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2020 — Total Non-Current Liabilities jumped 56.78% — and 2024, when it retreated 16.17%.
• Tracing ALGS's Total Non-Current Liabilities over 5 years: stood at $45.3 million in 2020, then advanced by 11.58% to $50.5 million in 2021, then declined by 16.99% to $41.9 million in 2022, then slipped by 24.02% to $31.9 million in 2023, then dropped by 16.17% to $26.7 million in 2024.
• The last three Total Non-Current Liabilities figures came in at $26.7 million (Q4 2024), $26.7 million (Q3 2024), and $30.1 million (Q2 2024), per Business Quant data.